Last reviewed · How we verify
IBI343,Gemcitabine, Albumin-bound Paclitaxel
IBI343,Gemcitabine, Albumin-bound Paclitaxel is a Nucleoside analog Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd.. It is currently in Phase 2 development for Breast cancer, Ovarian cancer, Pancreatic cancer.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase. Used for Breast cancer, Ovarian cancer, Pancreatic cancer.
At a glance
| Generic name | IBI343,Gemcitabine, Albumin-bound Paclitaxel |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | Nucleoside analog |
| Target | DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine is a chemotherapy medication used to treat various types of cancer, including breast, ovarian, pancreatic, and non-small cell lung cancer. It works by inhibiting DNA synthesis, which ultimately leads to cell death.
Approved indications
- Breast cancer
- Ovarian cancer
- Pancreatic cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Vomiting
Key clinical trials
- IBI343 in Combination Therapy for Advanced Malignant Solid Tumors (PHASE2)
- IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer (PHASE2)
- IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI343,Gemcitabine, Albumin-bound Paclitaxel CI brief — competitive landscape report
- IBI343,Gemcitabine, Albumin-bound Paclitaxel updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI
Frequently asked questions about IBI343,Gemcitabine, Albumin-bound Paclitaxel
What is IBI343,Gemcitabine, Albumin-bound Paclitaxel?
How does IBI343,Gemcitabine, Albumin-bound Paclitaxel work?
What is IBI343,Gemcitabine, Albumin-bound Paclitaxel used for?
Who makes IBI343,Gemcitabine, Albumin-bound Paclitaxel?
What drug class is IBI343,Gemcitabine, Albumin-bound Paclitaxel in?
What development phase is IBI343,Gemcitabine, Albumin-bound Paclitaxel in?
What are the side effects of IBI343,Gemcitabine, Albumin-bound Paclitaxel?
What does IBI343,Gemcitabine, Albumin-bound Paclitaxel target?
Related
- Drug class: All Nucleoside analog drugs
- Target: All drugs targeting DNA polymerase
- Manufacturer: Innovent Biologics (Suzhou) Co. Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer
- Indication: Drugs for Ovarian cancer
- Indication: Drugs for Pancreatic cancer
- Compare: IBI343,Gemcitabine, Albumin-bound Paclitaxel vs similar drugs
- Pricing: IBI343,Gemcitabine, Albumin-bound Paclitaxel cost, discount & access